Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965070 | 0.92 | TRPM8 (0.38) | TRPM8BACE1NR1H4PPARGPPARA | |
| SCHEMBL1966141 | 0.81 | EGFR (0.39) | BACE1SMN1; SMN2HPGDMAPTRAB9A | |
| SCHEMBL1966136 | 0.81 | EGFR (0.39) | BACE1SMN1; SMN2HPGDMAPTRAB9A | |
| SCHEMBL1968042 | 0.78 | TRPM8 (0.41) | TRPM8NR1H4PPARGPPARALTB4R | |
| SCHEMBL3087699 | 0.77 | TRPM8 (0.43) | TRPM8NR1H4PPARGPPARALTB4R | |
| SCHEMBL1969099 | 0.76 | TRPM8 (0.40) | TRPM8NR1H4PPARGPPARALTB4R | |
| SCHEMBL1969096 | 0.76 | TRPM8 (0.40) | TRPM8NR1H4PPARGPPARALTB4R | |
| SCHEMBL1119874 | 0.76 | TRPM8 (0.44) | TRPM8NR1H4PPARGPPARALTB4R | |
| SCHEMBL1965072 | 0.73 | TRPV1 (0.39) | BACE1SMN1; SMN2PPARGPPARALTB4R | |
| SCHEMBL1965069 | 0.73 | TRPV1 (0.39) | BACE1SMN1; SMN2PPARGPPARALTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2334658-A2 | ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031708-A2 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | TRPM8 4447/4885BACE1 4613/4885NR1H4 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.